CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for The Medicines Company is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

The Medicines Company
8 Sylvan Way
Phone: (973) 290-6000p:973 290-6000 Parsippany, NJ  07054  United States Fax: (973) 656-9898f:973 656-9898
This company was Merged or Acquired on 1/6/2020.
This company ceased filing statements with the SEC on 1/16/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201912/31/2018YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director MarkTimney 54 12/11/2018 12/11/2018
Chief Financial Officer, Treasurer Christopher J.Visioli 43 3/27/2018 3/27/2018
General Counsel, Secretary Stephen M.Rodin 43 3/3/2014 3/3/2014
6 additional Officers and Directors records available in full report.

Business Names
Business Name
Annovation BioPharma, Inc.
Incline Therapeutics Europe Ltd.
Incline Therapeutics, Inc.
19 additional Business Names available in full report.

General Information
Number of Employees: 62 (As of 12/31/2018)
Outstanding Shares: 79,933,176 (As of 11/21/2019)
Shareholders: 149
Stock Exchange: NASD
Federal Tax Id: 043324394
Fax Number: (973) 656-9898
Email Address: investor.relations@themedco.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023